This article is for informational and educational purposes only and does not constitute medical advice. Prostamax is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Prostamax is a synthetic tetrapeptide composed of lysine, glutamic acid, aspartic acid, and proline (Lys-Glu-Asp-Pro; single-letter: KEDP), developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the peptide bioregulator class — a series of short synthetic peptides proposed to modulate gene expression in a tissue-specific manner by interacting with DNA regulatory elements. Prostamax was characterized within the Khavinson series as a bioregulator for prostatic and urogenital tissue. Cell-based studies, conducted predominantly within the Khavinson laboratory, have examined associations between KEDP exposure and markers of prostate epithelial cell function, chromatin structure, and cellular-aging pathways; the shared Lys-Glu-Asp (KED) motif has additionally been discussed in relation to senescence markers and histone interaction. Molecular docking analyses have examined KEDP’s proposed interactions with gene promoter sequences. No peer-reviewed clinical trials evaluating Prostamax in human subjects have been published; all available mechanistic and pharmacological evidence derives from cell-based assays, animal studies, and in silico analyses.
1. Background
1.1 Peptide Bioregulators — The Khavinson Class
The peptide bioregulator concept was developed from the 1970s onward by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg, proposing that short peptides derived from organ-specific tissue extracts could influence gene expression in a tissue-targeted way. Prostamax is the prostatic and urogenital member of the series, and it is one of the few compounds in the class whose proposed DNA interaction has been examined by direct biochemical assay rather than computational modeling alone.
The class includes a range of named compounds, each proposed to target specific tissue types: Cortagen (Ala-Glu-Asp-Pro) for the nervous system, Pancreagen (Lys-Glu-Asp-Trp) for the pancreas, Livagen (Lys-Glu-Asp-Ala) for hepatic tissue, and Prostamax (Lys-Glu-Asp-Pro) for prostatic and urogenital tissue, among others. Notably, Prostamax’s KEDP sequence differs from the neural peptide Cortagen (AEDP) only at the first residue (lysine in place of alanine), and it shares the Lys-Glu-Asp (KED) N-terminal motif with several other bioregulators — illustrating how closely related sequences are assigned to distinct target tissues. The biological rationale for tissue specificity — why a tetrapeptide would preferentially influence gene expression in one tissue over another following systemic administration — has not been mechanistically established through independent research [2].
1.2 The Prostate and Urogenital Aging
The prostate is a glandular organ of the male urogenital system whose epithelial and stromal compartments undergo substantial age-related remodeling. Benign prostatic hyperplasia — a proliferative expansion of prostatic tissue — is among the most common age-associated conditions in men, and prostatic epithelial biology, hormonal signaling, and cellular senescence are active areas of aging research [4]. The prostate is also subject to chronic inflammatory and oxidative stress over the lifespan.
Prostamax’s development within the Khavinson group was based on the hypothesis that a short peptide modeled on prostate tissue-derived sequences could support gene expression programs relevant to prostatic epithelial function and resistance to age-related change. The specific relationship between the KEDP sequence and endogenous prostatic peptide content has not been independently characterized.
1.3 Historical and Research Context
The Prostamax literature differs from most of the series in one respect worth noting: alongside the usual cell-based studies and docking analyses from the Khavinson group, Fedoreyeva and colleagues published biochemical DNA and histone binding data in Biochemistry (Moscow) in 2011. That is a stronger class of mechanistic evidence than docking alone. It remains, however, work from within the same research tradition, and no laboratory outside it has published a replication or extended the binding data to a cellular context [1].
2. Molecular Structure
Prostamax is a tetrapeptide with the sequence Lys-Glu-Asp-Pro, abbreviated in single-letter code as KEDP. At four residues it sits alongside the other short tetrapeptides in the research peptide class, including Pancreagen (KEDW), Livagen (KEDA), and Cortagen (AEDP).
| Property | Detail |
|---|---|
| Full name | L-Lysyl-L-glutamyl-L-aspartyl-L-proline |
| Sequence (single-letter) | KEDP |
| Length | 4 amino acids (tetrapeptide) |
| Molecular formula | C₂₀H₃₃N₅O₉ |
| Molecular weight | ~487.5 Da |
| Net charge (physiological pH) | Mixed: one basic (Lys), two acidic (Glu, Asp), one imino acid (Pro) |
| Relationship to Cortagen | Differs from Cortagen (AEDP) only at position 1 (Lys vs Ala) |
| Post-translational modifications | None; fully synthetic |
| Water solubility | High |
| Class | Peptide bioregulator (Khavinson group) |
The C-terminal proline is of structural interest: as an imino acid with a rigid cyclic side chain, proline constrains backbone conformation and confers resistance to some exopeptidases, a feature shared with the neural peptide Cortagen (AEDP). The N-terminal lysine provides a positively charged ε-amino group, while the central glutamate and aspartate contribute negative charge. In the Khavinson group’s proposed DNA-binding framework, this arrangement of basic and acidic residues is proposed to mediate sequence-specific contacts with the DNA double helix. Whether the KEDP tetrapeptide interacts with genomic DNA in the manner proposed — and whether such interaction, if it occurs, is sufficient to alter transcription at physiologically meaningful concentrations — has not been independently established [2].
3. Proposed Mechanisms
The mechanisms below have been proposed in cell-based, animal model, and computational studies. None has been confirmed in controlled human interventional research. All mechanistic claims originate predominantly from the Khavinson group.
4. Key Research Findings
| Research Area | Evidence Level | Best Available Evidence |
|---|---|---|
| Prostate epithelial gene expression | Limited Cell-based only |
Khavinson group; cell culture studies |
| DNA interaction / promoter binding | Limited In silico + cell-based |
Tarnovskaya et al. 2014 (Adv Gerontol) |
| Nuclear penetration / histone interaction | Limited Cell-based / biochemical |
Fedoreyeva et al. 2011 (Biochemistry (Moscow)) |
| Chromatin / senescence markers (p16, p21) | Limited Cell-based / in silico |
Khavinson group; KED-motif studies |
| Animal model (urogenital) | Limited Khavinson group only |
Limited; predominantly originating laboratory |
| Human clinical evidence | Limited None published |
No peer-reviewed trials identified |
4.1 Prostate Cell and Chromatin Studies
Cell-based studies from the Khavinson group have examined the effect of KEDP and related Lys-Glu-Asp-containing peptides on prostatic and epithelial cell preparations, reporting associations with altered expression of genes related to cell function and aging, and with chromatin-level changes interpreted as increased accessibility of previously repressed genes [1]. These findings were framed as consistent with the general bioregulator hypothesis — that short peptides can shift gene expression programs in organ-specific target cells toward patterns associated with younger tissue. The specific gene targets, effect magnitudes, and experimental conditions have not been fully characterized in peer-reviewed literature accessible through international databases.
Conceptual schematic of the proposed interaction of KEDP with chromatin (DNA wrapped around a histone core), as described in the Khavinson group’s framework [2][3]. This diagram is illustrative and does not represent experimentally confirmed binding in prostatic cells.
4.2 DNA Interaction and Nuclear Penetration
Tarnovskaya et al. (2014) described the framework by which short bioregulator peptides are proposed to interact with DNA, with charged residues forming electrostatic contacts with the phosphate backbone and side chains participating in sequence-specific interactions in the major groove [2]. Separately, Fedoreyeva et al. (2011) reported that fluorescently labeled short peptides containing lysine, glutamate, and aspartate could penetrate into the nucleus of cultured cells and interact in vitro with deoxyribonucleotides, DNA, and histone proteins [3]. These biochemical observations are frequently cited as support for the proposed nuclear mechanism of the KED-motif peptides, of which KEDP is a member.
The applicability of these in silico and in vitro binding observations to transcriptional regulation in living prostatic tissue — where peptides must reach the nucleus at adequate concentration and compete with histones, transcription factors, and other chromatin-associated proteins — has not been independently verified with functional assays in prostate cells, and no causal link between nuclear binding and a physiological prostatic outcome has been established.
4.3 The KED Motif, Senescence, and Tissue Specificity
Prostamax (KEDP) shares its Lys-Glu-Asp N-terminal motif with several other Khavinson bioregulators — the KED tripeptide itself (assigned to vascular and gonadal tissue as Vesugen and Testagen), Pancreagen (KEDW), and Livagen (KEDA). The KED motif has been specifically discussed in relation to the regulation of cellular-senescence markers such as p16 and p21. At the same time, Prostamax differs from the neural peptide Cortagen (AEDP) by a single N-terminal residue. This pattern — a shared motif spanning multiple target tissues, and single-residue differences distinguishing peptides assigned to entirely different organs — highlights the central unresolved question of the bioregulator hypothesis: the molecular basis for tissue-preferential activity has not been established in the independent literature [2].
5. Evidence Status
| Evidence Type | Current Status |
|---|---|
| Biochemical DNA and histone binding studies | Published (Fedoreyeva et al. 2011, Biochemistry (Moscow)) — actual binding data, not docking |
| Cell-based prostatic and epithelial studies | Published (Khavinson group; predominantly Russian-language journals) |
| In silico docking to gene promoter sequences | Published; complements but does not replace the biochemical work |
| Prostate epithelial function and chromatin structure markers | Reported at marker level in cell preparations |
| Binding shown to be sequence-specific in a cellular context | Not established; in vitro binding does not demonstrate promoter selection in a living cell |
| Animal studies of prostatic or urogenital function | Limited; predominantly from the originating laboratory |
| Human urogenital outcomes, safety or pharmacokinetics | No published trial at any phase |
What We Still Don’t Know
- Whether the proposed DNA/chromatin mechanism operates in living prostate cells: The in silico docking and in vitro binding studies propose interactions between KEDP (and the KED motif) and DNA, histones, and chromatin, but whether this peptide at pharmacologically achievable intracellular concentrations produces a functional transcriptional change in intact prostatic cells has not been demonstrated by independent investigators.
- Whether tissue specificity exists and how it would operate: The classification of Prostamax as a prostatic bioregulator implies tissue-preferential activity, yet its sequence is a single residue away from the neural peptide Cortagen (AEDP) and shares a motif with vascular, gonadal, hepatic, and pancreatic peptides. No pharmacokinetic study has demonstrated preferential distribution of KEDP to prostatic tissue.
- Whether the senescence-marker associations are causal: Discussion of the KED motif in relation to p16 and p21 is largely at the level of association and computational proposal. Whether KEDP causally modulates these senescence markers in prostatic cells, and with what functional consequence, has not been established in the independent literature.
- Human safety and pharmacokinetics: No published phase 1 trial characterizes the safety, tolerability, half-life, or target-tissue distribution of Prostamax in humans. Although the C-terminal proline may confer some peptidase resistance, human pharmacokinetic data are absent.
- Effective dose and route of administration in any in vivo context: Dose-response data in animal models and the pharmacologically active concentration range in living prostatic tissue are not characterized in the independent literature.
- Relationship to established prostate therapeutics: How, if at all, Prostamax relates mechanistically or functionally to validated approaches in prostatic health has not been studied; no comparative data exist.
6. Limitations of Current Research
References
- Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Basel: Karger; 2005. ISBN 3-8055-7833-7.
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of Short Peptides Interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. “Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.” Biochemistry (Moscow). 2011;76(11):1210–1219. doi:10.1134/S0006297911110022
- Untergasser G, Madersbacher S, Berger P. “Benign prostatic hyperplasia: age-related tissue-remodeling.” Experimental Gerontology. 2005;40(3):121–128. doi:10.1016/j.exger.2004.12.008